FDA Approval: Adjuvant Alectinib for Resected NSCLC

Podcast | English | 2024 | 38 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which included patients with resected stage II/III NSCLC with an ALK fusion.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Benjamin Solomon, MBBS, PhD, FRACP, Professor, Department of Medical Oncology, Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia